Author:
Daniels Martin A.,Fischer-Posovszky Pamela,Boschmann Michael,Jumpertz-von Schwartzenberg Reiner,Müller Timo D.,Sandforth Leontine,Frank-Podlech Sabine,Hülskämper Sonja,Peter Andreas,Wabitsch Martin,Jordan Jens,Birkenfeld Andreas L.
Abstract
IntroductionAtrial natriuretic peptide (ANP), a hormone secreted from the heart, controls cardiovascular and renal functions including arterial blood pressure and natriuresis. ANP also exerts metabolic effects in adipose tissue, liver and skeletal muscle, and interacts with the secretion of adipokines. We tested the hypothesis that ANP lowers concentrations of the anorexigenic adipokine leptin in healthy humans in vivo.MethodsHuman ANP or matching placebo was infused intravenously (iv) into healthy men in a controlled clinical trial.ResultsWithin 135 minutes of iv ANP infusion, we observed an acute decrease in plasma leptin levels compared to controls. Free fatty acids markedly increased with ANP infusion in vivo, indicating activated lipolysis. In human SGBS adipocytes, ANP suppressed leptin release.DiscussionThe study shows that the cardiac hormone ANP reduces the levels of the anorexigenic adipokine leptin in healthy humans, providing further support for ANP as a cardiomyokine in a heart - adipose tissue axis. (registered in the German Clinical Trials Register and the WHO International Clinical Trials Registry Platform was granted under DRKS00024559)
Subject
Endocrinology, Diabetes and Metabolism
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献